Gestodene

7 Drugs classified under this active ingredient

Estrogen, Progestogen. Ethinylestradiol 0.02 mg, Gestodene 0.075 mg.
TABS. 1X21 / 3X21
1 tab. dly for 21 days, foll. by 7 days tab. free. Start on 1st day of cycle. See lit.
Oral contracept.
C/I:  Hypersens. to active ingredients or excipients;
presence or risk of ATE – current ATE or hist. of ATE (e.g. MI) or prodrom. condit. (e.g. angina p.). Cerebrovas. dis. – current stroke, hist. of stroke or prodrom. condit. (e.g. TIA), known heredit. or acquired predisposit. for arterial thromboembol., such as hyperhomocysteinaemia and APLA (anticardiolipin-antibodies, lupus anticoag.), hist. of migraine with focal neurologic. sympt., high risk of arterial thromboembol. due to mult. risk factors or to the presence of one ser. risk factor: (e.g. diabetes mell.  with vasc. sympt., sev. hypertens., sev. dyslipoproteinaemia), coronary dis.; presence or risk VTE: current VTE (on anticoagul.) or hist. of (e.g DVT, PE), known heredit. or acquir. predisposit. for venous thromboemb., such as APC-resist., (includ. Factor V Leiden), antithrombin-III-defic., protein C defic., protein S defic., major surg. with prolong. immobilizat., high risk of VTE due to the pres. of mult. risk fact.; thrombogenic valvulopathy; thrombogenic arrhythmias;  susp. or confirmed breast cancer;  susp. or confirmed oestrogen-sensitive neoplasms (endometrial etc.);  hepatic adenoma or carcin.;  sev. hepatic disord. - until hepatic funct. has normalised;
abnormal vaginal bleed. of unknown cause; susp. or confirmed pregn.; pancreatit. assoc. with sev. hypertriglyceridemia (current or hist.); concom. use with ombitasvir/paritaprevir/ritonavir and dasabuvir or glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir. See lit

Estrogen, Progestogen. Ethinylestradiol 0.03 mg, Gestodene 0.075 mg.
TABS 1/3 x 21.
1 tab. dly. See lit.
Oral Contracept.
C/I:  Hypersens. to act. ingred. or any of excipients. Presen. or risk VTE: Thrombophleb. or venous thromboem.  – curr. VTE (on anticoagul.) or hist. of (e.g DVT, PE) or other dis., assoc. with an incr. thromboemb. risk such as thrombogen. valvulopathies and thrombogenic rhythm disord. (current / hist.). Known heredit. or acquir. predisposit. for venous thromboemb., such as APC-resistance, (includ. Factor V Leiden), antithrombin-III-defic., protein C defic., protein S defic. Major surg. with prolong. immobiliz. A high risk of VTE due to the presen. of multi. risk fact. Presen. or risk of arterial thromboem. (ATE): ATE – current ATE, hist. of ATE (e.g. MI) or prodrom. condition (e.g. angina p.). Cerebrovasc. or coron. artery dis. – curr. stroke, hist. of stroke or prodrom. condit. (e.g. transient ischaemic attack, TIA). Known hered. or acq. predisposit. for ATE, such as hyperhomocysteinaemia and APLA (anticardiolipin-antibodies, lupus anticoag.). Hist. of migraine with focal neurological sympt. A high risk of ATE due to mult. risk factors or to the pres. of one serious risk factor: (e.g. diabetes mell.  with vasc. sympt., sev. hypertens., sev. dyslipoproteinaemia). Known/suspect. carcin. of the breast, carcin. of the endometr. or other known/suspect. estrogen-dependent neoplasia. Undiagn. abnormal vag.bleed. Hepat. adenom./ carcinom., acute /chron. liver dis., as long as liver funct. has not returned to normal. Pancreat. assoc. with severe hypertriglyceridem. (current /history). Known/ suspect. pregn .Concom./use with med. products contain. ombitasvir/paritaprevir/ritonavir and dasabuvir. or meds. contain.  glecaprevir/pibrentasvir. See lit.

Estrogen, Progestogen. Ethinylestradiol 0.03 mg, Gestodene 0.075 mg.
C. TABS: 1, 3 x 21. 1 tab. dly. for 21 days
start. on 1st day of bleeding. See lit.
Hormonal contracept.

Estrogen, Progestogen. Ethinylestradiol 0.020 mg, Gestodene 0.075 mg.
TABS: 1 x 21, 3 x 21. 1 tab. dly for 21 days, foll. by 7 days tab. free. Start on 1st day of cycle.
Oral contracept.
C/I: Cerebrovasc. dis. – current, history of stroke or prodromal condit. (e.g., TIA)
Known hered./acquir. predisposit. for arterial thromboembolism, such as
hyperhomocysteinaemia and
antiphospholipid-antibod. (anticardiolipin-antibod.,lupus anticoagulant).
History of migraine with focal neurology. sympt.
A high risk of arterial thromboembolism due to multiple risk factor. or to the presence of one serious risk factor( e.g. diabetes mell. with vascular sympt.(micro or macroangiopathy), severe hypertens., severe dyslipoproteinaemia
Coronary dis.
- Presence or risk of VTE, current VTE (on anticoagul.) or history of VTE (eg. DVT,PE)
Known hered.or acquir. predisposit. for venous thromboembolism, such as
APC-resistance, (include. Factor V Leiden), antithrombin-III-defic., protein C
defic., protein S defic.
Major surg. with prolong. immobilization.
A high risk of venous thromboembolism due to the presence of multiple risk factors.
- Thrombogenic valvulopathy;
- Thrombogenic arrhythmias;
- Suspect./ confirm.breast cancer;
- Suspect./ confirm. oestrogen-sensit. neoplasms (endometrial etc.);
- Hep. adenoma /carcinoma;
- Severe hep. disord.- until hepatic function has normalised;
- Abnorm. vag.l bleed.of unknown cause;
Suspected or confirmed preg.
- Hypersens.
- Pancreatit. associated with severe hypertriglyceridemia (current or history).
Concom.use with ombitasvir/paritaprevir/ritonavir and dasabuvir ,or glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.

Estrogen, Progestogen. Ethinylestradiol 0.02 mg, Gestodene 0.075 mg.
TABS: 1 x 21, 3 x 21. 1 tab for 21 days on
1st day of bleed., foll. by 7 days tab
free.
Oral contracept.

Estrogen, Progestogen. Ethinylestradiol 0.015 mg, Gestodene 0.06 mg.
TABS.: 28. First tab (yellow) on 1^st day of menstr. cycle, ending cycle with 4 placebo tabs. See lit.
Oral hormonal contracept.
C/I: Hypersens.
- Pres. or risk of venous thromboembol. (VTE). Pres. or risk of arterial thromboembol. (ATE). See prescr. inform. for full details
- Known or susp. carcin. of the breast
- Carcin. of the endometr. or other known or susp. estrogen-depend.
neoplasia
- Hep. adenomas or carcin., or active liver dis., as long as liver funct. tests have not return. to normal
- Undiagn. genital bleeding
- Concomit. use with certain anti-viral hepat. C virus (HCV) prod. such as ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.